Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06393335 is registered in ClinicalTrials.gov with The Children's Hospital of Zhejiang University School of Medicine as lead sponsor.

NCT NCT06393335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06393335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Lead sponsor
The Children's Hospital of Zhejiang University School of Medicine
Phase
Phase 1
Overall status
Unknown status
Start date
May 15, 2024
Completion date
March 15, 2026
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, non-hodgkin lymphoma